Details of Drug

Drug General Information (ID: D1086)
Drug Name	Monopotassium phosphate
Drug Type	Small molecule
Drug Synonymous	Potassium dihydrogen phosphate; 7778-77-0; Potassium phosphate monobasic; MONOPOTASSIUM PHOSPHATE; Monobasic potassium phosphate; Phosphoric acid, monopotassium salt; Potassium acid phosphate; Potassium phosphate, monobasic; Monopotassiumphosphate; Potassium dihydrogen orthophosphate; Monopotassium monophosphate; Monopotassium orthophosphate; Monopotassium dihydrogen phosphate; Potassium dihydrogenorthophosphate; potassium dihydrogenphosphate; potassium;dihydrogen phosphate; Sorensen's potassium phosphate; Potassium phosphate (K(H2PO4)); KH2PO4; UNII-4J9FJ0HL51; Orthophosphoric acid, monopotassium salt; CHEBI:63036; MFCD00011401; Phosphoric acid, potassium salt (1:1); 4J9FJ0HL51; MKP; Chlorine Titrimeter Reagent; Buffer Solution, pH 6.00; Buffer Solution, pH 7.00; Buffer Solution, pH 7.40; MFCD00147253; Potassium dihydrogen orthophosphate(V); potassium biphosphate; HSDB 5046; Buffer Solution, pH 7.00, Color-Coded Yellow; Potassium orthophosphate, dihydrogen; EINECS 231-913-4; EPA Pesticide Chemical Code 076413; Potassium hydrogen phosphate (KH2PO4); Potassium phosphate, monobasic [NF]; Phosphoric acid, potassium salt (1:?); mono potassium phosphate; mono-potassium phosphate; prim.-Potassium phosphate; H2KO4P; EC 231-913-4; Potassium phosphate,monobasic; potassium di-hydrogen phosphate; CHEMBL1200925; DTXSID0035667; Potassium Dihydrogen Phosphate,(S); EINECS 240-213-8; BDBM50004328; Monopotassium dihydrogen monophosphate; AKOS015902364; AKOS028109678; Monopotassium dihydrogen orthophosphate; DB09413; Potassium dihydrogen phosphate monobasic; Potassium phosphate monobasic (anhydrous); Potassium phosphate, monobasic (JAN/NF); Potassium dihydrogen phosphate, Puratronic?; B7291; FT-0645117; W8424; D02050; Potassium phosphate monobasic, Trace metals grade; Q415049; Potassium phosphate, 0.2M buffer solution, pH 7.0; Potassium phosphate, 0.2M buffer solution, pH 7.2; Potassium phosphate, 0.2M buffer solution, pH 7.4; Potassium phosphate, 0.2M buffer solution, pH 7.5; Potassium phosphate, 0.2M buffer solution, pH 7.6; Potassium phosphate, 0.5M buffer solution, pH 7.0; Potassium phosphate, 0.5M buffer solution, pH 7.4; Potassium phosphate, 0.5M buffer solution, pH 7.5; Potassium phosphate, 0.5M buffer solution, pH 7.6; UNII-B7862WZ632 component GNSKLFRGEWLPPA-UHFFFAOYSA-M; Potassium phosphate monobasic powder suitable for cell culture; Buffer solution, pH 1.68 (+/-0.01 at 25?C), No Color, Specpure, NIST Traceable Click to Show/Hide
Therapeutic Class	Minerals And Electrolytes
Structure
Structure	3D Structure		2D Structure
Formula	H2KO4P
InChI	InChI=1S/K.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+1;/p-1
InChIKey	GNSKLFRGEWLPPA-UHFFFAOYSA-M
Canonical SMILES	OP(=O)(O)[O-].[K+]
External Link
External Link	Pubchem ID	516951

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM005 Affected excretion pathways AM006 Pharmacodynamic additive effects AM007 Pharmacodynamic antagonistic effects BM029 Altered urine pH BM058 Increased risk of hyperkalemia BM063 Increased risk of hypocalcemia BM064 Increased risk of hypoglycemia BM107 Attenuated pharmacological effects (Unspecific) BM109 Increased risk of other adverse reactions (Unspecific)
Relation Graph

Full list of drugs interacting with Monopotassium phosphate
Affected excretion pathways
	Altered urine pH					Drug Num: 10
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0074		Amphetamine	C9H13N	3007	Moderate		Inter Info	[19], [20], [21]
D0165		Benzphetamine	C17H21N	5311017	Moderate		Inter Info	[19], [20], [21]
D0465		Dextroamphetamine	C9H13N	5826	Moderate		Inter Info	[19], [20], [21]
D0937		Lisdexamfetamine	C15H25N3O	11597698	Moderate		Inter Info	[19], [20], [21]
D1012		Metamfetamine	C10H15N	10836	Moderate		Inter Info	[19], [20], [21]
D0579		Ephedrine	C10H15NO	9294	Minor		Inter Info	[31], [32], [33]
D0664		Flecainide	C17H20F6N2O3	3356	Minor		Inter Info	[34]
D1017		Methadone	C21H27NO	4095	Minor		Inter Info	[38], [39], [40]
D1054		Mexiletine	C11H17NO	4178	Minor		Inter Info	[41]
D1363		Pseudoephedrine	C10H15NO	7028	Minor		Inter Info	[31], [32], [33]
Pharmacodynamic additive effects
	Increased risk of hyperkalemia					Drug Num: 45
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0058		Amiloride	C6H8ClN7O	16231	Major		Inter Info	[1], [2], [3]
D0138		Azilsartan medoxomil	C30H24N4O8	135409642	Major		Inter Info	[4], [5], [3]
D0156		Benazepril	C24H28N2O5	5362124	Major		Inter Info	[6], [7], [8]
D0254		Captopril	C9H15NO3S	44093	Major		Inter Info	[6], [7], [8]
D0567		Enalapril	C20H28N2O5	5388962	Major		Inter Info	[6], [7], [8]
D0585		Eplerenone	C24H30O6	443872	Major		Inter Info	[9], [10]
D0587		Eprosartan	C23H24N2O4S	5281037	Major		Inter Info	[4], [5], [3]
D0695		Fosinopril	C30H46NO7P	55891	Major		Inter Info	[6], [7], [8]
D0844		Irbesartan	C25H28N6O	3749	Major		Inter Info	[4], [5], [3]
D0938		Lisinopril	C21H31N3O5	5362119	Major		Inter Info	[6], [7], [8]
D0954		Losartan	C22H23ClN6O	3961	Major		Inter Info	[4], [5], [3]
D1082		Moexipril	C27H34N2O7	91270	Major		Inter Info	[6], [7], [8]
D1170		Olmesartan	C24H26N6O3	158781	Major		Inter Info	[4], [5], [3]
D1256		Perindopril	C19H32N2O5	107807	Major		Inter Info	[6], [7], [8]
D1369		Quinapril	C25H30N2O5	54892	Major		Inter Info	[6], [7], [8]
D1379		Ramipril	C23H32N2O5	5362129	Major		Inter Info	[6], [7], [8]
D1501		Spironolactone	C24H32O4S	5833	Major		Inter Info	[1], [2], [3]
D1545		Telmisartan	C33H30N4O2	65999	Major		Inter Info	[4], [5], [3]
D1618		Trandolapril	C24H34N2O5	5484727	Major		Inter Info	[7], [8], [6]
D1631		Triamterene	C12H11N7	5546	Major		Inter Info	[1], [2], [3]
D1645		Trimethoprim	C14H18N4O3	5578	Major		Inter Info	[13], [14], [15]
D1679		Valsartan	C24H29N5O3	60846	Major		Inter Info	[4], [5], [3]
D0038		Aliskiren	C30H53N3O6	5493444	Moderate		Inter Info	[16], [17], [18]
D0210		Bromfenac	C15H12BrNO3	60726	Moderate		Inter Info	[22], [23], [24]
D0476		Diclofenac	C14H11Cl2NO2	3033	Moderate		Inter Info	[22], [23], [24]
D0489		Diflunisal	C13H8F2O3	3059	Moderate		Inter Info	[22], [23], [24]
D0536		Drospirenone	C24H30O3	68873	Moderate		Inter Info	[25], [26]
D0624		Etodolac	C17H21NO3	3308	Moderate		Inter Info	[22], [23], [24]
D0645		Fenoprofen	C15H14O3	3342	Moderate		Inter Info	[22], [23], [24]
D0680		Flurbiprofen	C15H13FO2	3394	Moderate		Inter Info	[22], [23], [24]
D0786		Ibuprofen	C13H18O2	3672	Moderate		Inter Info	[22], [23], [24]
D0800		Indomethacin	C19H16ClNO4	3715	Moderate		Inter Info	[22], [23], [24]
D0881		Ketoprofen	C16H14O3	3825	Moderate		Inter Info	[22], [23], [24]
D0882		Ketorolac	C15H13NO3	3826	Moderate		Inter Info	[22], [23], [24]
D0988		Meclofenamic acid	C14H11Cl2NO2	4037	Moderate		Inter Info	[22], [23], [24]
D0991		Mefenamic acid	C15H15NO2	4044	Moderate		Inter Info	[22], [23], [24]
D0995		Meloxicam	C14H13N3O4S2	54677470	Moderate		Inter Info	[22], [23], [24]
D1097		Nabumetone	C15H16O2	4409	Moderate		Inter Info	[22], [23], [24]
D1109		Naproxen	C14H14O3	156391	Moderate		Inter Info	[22], [23], [24]
D1196		Oxaprozin	C18H15NO3	4614	Moderate		Inter Info	[22], [23], [24]
D1274		Phenylbutazone	C19H20N2O2	4781	Moderate		Inter Info	[22], [23], [24]
D1300		Piroxicam	C15H13N3O4S	54676228	Moderate		Inter Info	[22], [23], [24]
D1520		Sulindac	C20H17FO3S	1548887	Moderate		Inter Info	[22], [23], [24]
D1606		Tolmetin	C15H15NO3	5509	Moderate		Inter Info	[22], [23], [24]
D1608		Tolvaptan	C26H25ClN2O3	216237	Moderate		Inter Info	[30]
	Increased risk of hypocalcemia					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0694		Foscarnet	CH3O5P	3415	Moderate		Inter Info	[27], [28], [29]
	Increased risk of hypoglycemia					Drug Num: 14
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0807		Insulin aspart (aspart protamine)	C256H381N65O79S6	118984445	Minor		Inter Info	[35], [36], [37]
D0808		Insulin aspart (aspart)	C256H381N65O79S6	118984445	Minor		Inter Info	[35], [36], [37]
D0810		Insulin detemir	C267H402N64O76S6	16137271	Minor		Inter Info	[35], [36], [37]
D0811		Insulin glargine	C267H404N72O78S6	118984454	Minor		Inter Info	[35], [36], [37]
D0812		Insulin glulisine	C258H384N64O78S6	16136701	Minor		Inter Info	[35], [36], [37]
D0813		Insulin human	C257H383N65O77S6	118984375	Minor		Inter Info	[35], [36], [37]
D0814		Insulin human (inhalation, rapid acting)	C257H383N65O77S6	118984375	Minor		Inter Info	[35], [36], [37]
D0815		Insulin human (isophane)	C257H383N65O77S6	118984375	Minor		Inter Info	[35], [36], [37]
D0816		Insulin human (regular)	C257H383N65O77S6	118984375	Minor		Inter Info	[35], [36], [37]
D0817		Insulin human (zinc extended)	C257H383N65O77S6	118984375	Minor		Inter Info	[35], [36], [37]
D0818		Insulin human (zinc)	C257H383N65O77S6	118984375	Minor		Inter Info	[35], [36], [37]
D0819		Insulin lispro	C257H389N65O77S6	16132438	Minor		Inter Info	[35], [36], [37]
D0820		Insulin lispro (protamine)	C257H389N65O77S6	16132438	Minor		Inter Info	[35], [36], [37]
D0809		Insulin degludec	C274H411N65O81S6	118984462	Minor		Inter Info	[35], [36], [37]
	Increased risk of other adverse reactions (Unspecific)					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0221		Burosumab	NA	NA	Major		Inter Info	[11]
Pharmacodynamic antagonistic effects
	Attenuated pharmacological effects (Unspecific)					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0590		Erdafitinib	C25H30N6O2	67462786	Major		Inter Info	[12]

References
1	Shapiro S, Slone D, Lewis GP, Jick H "Fatal drug reactions among medical inpatients." JAMA 216 (1971): 467-72. [PMID: 5107928]
2	McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970): 58-70. [PMID: 5410663]
3	Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J "Hyperkalemia in the elderly." Clin Chem 30 (1984): 1409-12. [PMID: 6744599]
4	Obialo CI, Ofili EO, Mirza T "Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease." Am J Cardiol 90 (2002): 663-5. [PMID: 12231103]
5	Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812. [PMID: 14525902]
6	Product Information. K-Dur (potassium chloride). Schering Laboratories, Kenilworth, NJ.
7	Warren SE, O'Connor DT "Hyperkalemia resulting from captopril administration." JAMA 244 (1980): 2551-2. [PMID: 7001073]
8	Chan TY, Critchley JA "Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements." Drug Saf 7 (1992): 159-61. [PMID: 1605901]
9	Product Information. Inspra (eplerenone). Searle, Chicago, IL.
10	Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006): 49-58. [PMID: 16373465]
11	Product Information. Crysvita (burosumab). Ultragenyx Pharmaceutical, Novato, CA.
12	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
13	Noto H, Kaneko Y, Takano T, Kurokawa K "Severe hyponatremia and hyperkalemia induced by trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia." Intern Med 34 (1995): 96-9. [PMID: 7727887]
14	Witt JM, Koo JM, Danielson BD "Effect of standard-dose trimethoprim/sulfamethoxazole on the serum potassium concentration in elderly men." Ann Pharmacother 30 (1996): 347-50. [PMID: 8729886]
15	Canaday DH, Johnson JR "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 438. [PMID: 8304666]
16	Tapaninen T, Neuvonen PJ, Niemi M "Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren." Clin Pharmacol Ther 88 (2010): 339-42. [PMID: 20664534]
17	Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP "Clinical pharmacokinetics and pharmacodynamics of aliskiren." Clin Pharmacokinet 47 (2008): 515-31. [PMID: 18611061]
18	Product Information. Tekturna (aliskiren). Novartis Pharmaceuticals, East Hanover, NJ.
19	Beckett AH, Rowland M, Turner P "Influence of urinary pH on excretion of amphetamine." Lancet 1 (1965): 303. [PMID: 14247879]
20	Product Information. Dexedrine (dextroamphetamine) SmithKline Beecham, Philadelphia, PA.
21	Gary NE, Saidi P "Methamphetamine intoxication. A speedy new treatment." Am J Med 64 (1978): 537-40
22	Product Information. K-Phos Original (potassium acid phosphate). Beach Pharmaceuticals, Tampa, FL.
23	Product Information. Potassium Chloride ER (potassium chloride). Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.
24	Cerner Multum, Inc. "Australian Product Information.".
25	Ponce SP, Jennings AE, Madias NE, Harrington JT "Drug-induced hyperkalemia." Medicine (Baltimore) 64 (1985): 357-70. [PMID: 2865667]
26	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
27	Foscarnet: a review. Drugs 41 (1991): 106-29. [PMID: 1706982]
28	Product Information. Foscavir (foscarnet). Astra USA, Westborough, MA.
29	Youle M, Clarbour J, Gazzard B, Chanas A "Severe hypocalcemia in AIDS patients treated with foscarnet and pentamidine." Lancet 1 (1988): 1455-6. [PMID: 2898602]
30	Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
31	Brater DC, Kaojarern S, Benet LZ, et al "Renal excretion of pseudoephedrine." Clin Pharmacol Ther 28 (1980): 690-4. [PMID: 7438686]
32	Kuntzman RG, Tsai I, Brand L, Mark LC "The influence of urinary pH on the plasma half-life of pseudoephedrine in man and dog and a sensitive assay for its determination in human plasma." Clin Pharmacol Ther 12 (1971): 62-7. [PMID: 5541135]
33	Wilkinson GR, Beckett AH "Absorption metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output." J Pharmacol Exp Ther 162 (1968): 139-47. [PMID: 5656593]
34	Hertrampf R, Gundert-Remy U, Beckmann J, et al "Elimination of flecainide as a function of urinary flow rate and pH." Eur J Clin Pharmacol 41 (1991): 61-3. [PMID: 1782979]
35	DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ "The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man." J Clin Invest 55 (1975): 845-55
36	Hiatt N, Davidson MB, Bonorris G "The effect of potassium chloride infusion on insulin secretion in vivo." Horm Metab Res 4 (1972): 64-8
37	Conn HO "Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism." Am J Med Sci 259 (1970): 394-404
38	Benmebarek M, Devaud C, Gex-Fabry M, et al. "Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone." Clin Pharmacol Ther 76 (2004): 55-63
39	Nilsson M-I, Widerlov E, Meresaar U, Anggard E "Effect of urinary pH on the disposition of methadone in man." Eur J Clin Pharmacol 22 (1982): 337-42
40	Oda Y, Kharasch ED "Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation." J Pharmacol Exp Ther 298 (2001): 1021-32
41	Mitchell BG, Clements JA, Pottage A, Prescott LF "Mexiletine disposition: individual variation in response to urine acidification and alkalinisation." Br J Clin Pharmacol 16 (1983): 281-4. [PMID: 6626420]

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence